The direct-to-patient model is changing how diabetes companies reach and support patients. Pharma companies are building direct access channels that combine therapy with monitoring, adherence support, and patient services, while device manufacturers generate rich patient data but have yet to translate that position into an owned patient relationship.

Stout Strategy’s latest healthcare perspective examines what this shift means for diabetes device manufacturers as drug, device, data, and patient support move toward a more integrated model.